EU companies increasing R&D


Companies in the EU are increasing their investment in R&D, despite the difficult economic conditions, according to a report from the European Commission that looked at the global top 1500 R&D investors.

Investment rose by 8.9% in 2011, compared with a rise of 6.1% in 2010, putting the EU above the global average of 7.6% growth, but just below the US figure of 9% growth.

In absolute terms, the global pharma industry invested the most in R&D, over €90 billion (£72 billion) in 2011. But it was in second place within the EU, behind the automotive industry. Three drug makers nevertheless made it into the top ten EU investors in R&D: Sanofi at four, GlaxoSmithKline at five and AstraZeneca at eight.

But the Commission found the largest increases in investment in the banking, industrial engineering and automotive industries.

According to the report, the EU remains a highly attractive place for investment in R&D, thanks to: ‘developed markets with a sophisticated demand [so-called lead markets]; the quality and quantity of its pool of skilled labour; public support [of] R&D and the quality of its scientific and technological base’.


Related Content

Europe risks being outstripped by R&D rivals

26 October 2011 News Archive

news image

Investment in R&D by top European firms grew by 6 per cent last year, but competitors are growing faster

What's in store for European biotech?

28 October 2010 Premium contentFeature

news image

The global economic crisis has made funding even harder to come by, but positive long-term trends provide some cause for opti...

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent